We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware
Read MoreHide Full Article
For Immediate Release
Chicago, IL –August 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Celgene , Exxon Mobil (XOM - Free Report) , Berkshire Hathaway (BRK.B - Free Report) , Phillips 66 (PSX - Free Report) and VMware .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Celgene, Exxon Mobil and Berkshire Hathaway
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene, Exxon Mobil and Berkshire Hathaway. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Celgene’s shares have underperformed the Zacks Biomedical and Genetics industry in the last three months, gaining +3.6% vs. +10.0%. Celgene’s second-quarter results were impressive as the company beat on both sales and earnings. Revlimid sales were impressive yet again, along with Pomalyst and Otezla.
The increase in annual guidance on the back of Revlimid sales should boost investors’ sentiment, given the recent spate of pipeline setbacks. The company is focused on the next cycle of innovation with five late stage candidates. In a bid to revive its pipeline, Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline.
Celgene expects to submit its NDA for fedratinib in myelofibrosis by the end of 2018. The company remains on track with submissions for ozanimod, both in the United States and EU, for relapsing multiple sclerosis in the first quarter of 2019.
Shares of Exxon Mobil have gained +6.1% in the last three months, outperforming the Zacks Oil and Gas - Integrated industry, which gained +2.0% over the same period. The company has a leading position in the energy industry owing to the size and diversity of its asset base, both in terms of business mix and geographical footprint.
With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.
Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. However, significant turnaround activities, hurting throughput volumes, led to lower-than-expected results in the second quarter. Moreover, ExxonMobil’s exit from a joint venture in Russia could limit the company’s upside.
Buy-ranked Berkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+11.2% vs. 8.9%). Berkshire’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on acquisitions.
Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level further adds an impetus to the company. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern. Huge capital expenses due to railroad operations also emerge as headwinds. Capital expenditure is estimated at $10 billion in 2018.
Other noteworthy reports we are featuring today include Phillips 66 and VMware.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware
For Immediate Release
Chicago, IL –August 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Celgene , Exxon Mobil (XOM - Free Report) , Berkshire Hathaway (BRK.B - Free Report) , Phillips 66 (PSX - Free Report) and VMware .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Celgene, Exxon Mobil and Berkshire Hathaway
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene, Exxon Mobil and Berkshire Hathaway. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Celgene’s shares have underperformed the Zacks Biomedical and Genetics industry in the last three months, gaining +3.6% vs. +10.0%. Celgene’s second-quarter results were impressive as the company beat on both sales and earnings. Revlimid sales were impressive yet again, along with Pomalyst and Otezla.
The increase in annual guidance on the back of Revlimid sales should boost investors’ sentiment, given the recent spate of pipeline setbacks. The company is focused on the next cycle of innovation with five late stage candidates. In a bid to revive its pipeline, Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline.
Celgene expects to submit its NDA for fedratinib in myelofibrosis by the end of 2018. The company remains on track with submissions for ozanimod, both in the United States and EU, for relapsing multiple sclerosis in the first quarter of 2019.
Shares of Exxon Mobil have gained +6.1% in the last three months, outperforming the Zacks Oil and Gas - Integrated industry, which gained +2.0% over the same period. The company has a leading position in the energy industry owing to the size and diversity of its asset base, both in terms of business mix and geographical footprint.
With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.
Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. However, significant turnaround activities, hurting throughput volumes, led to lower-than-expected results in the second quarter. Moreover, ExxonMobil’s exit from a joint venture in Russia could limit the company’s upside.
Buy-ranked Berkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+11.2% vs. 8.9%). Berkshire’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on acquisitions.
Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level further adds an impetus to the company. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern. Huge capital expenses due to railroad operations also emerge as headwinds. Capital expenditure is estimated at $10 billion in 2018.
Other noteworthy reports we are featuring today include Phillips 66 and VMware.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.